Key result
LU 135.252 inhibits ET-1-induced arrhythmias and MAPD prolongation in dogs but not ischemic changes.
Why the study?
Does the endothelin-A-receptor antagonist LU 135.252 prevent ventricular arrhythmias caused by intrapericardial endothelin-1 infusion in open-chest dogs?
Does the endothelin-A-receptor antagonist LU 135.252 prevent ventricular arrhythmias caused by intrapericardial endothelin-1 infusion in open-chest dogs?
The endothelin-A-receptor antagonist LU 135.252 inhibits the arrhythmogenic and electrophysiological effects of pericardial endothelin-1 infusion in a canine model, although it does not prevent ischemic changes.
Answers are grounded in this paper and cite their sources.
Supports ET-A blockade in ET-1 arrhythmia models; leaves open translation to human ischemic arrhythmias.
Intrapericardial endothelin-1 (ET-1) infusion causes dose-dependent severe ventricular arrhythmias. We examined the effects of the endothelin-A- (ETA) receptor antagonist LU 135.252 (LU) on ET-1-induced arrhythmias on six open-chest mongrel dogs. Ten minutes after an intravenous bolus of LU (5 mg/kg), ET- 1 (33 pmol/kg/min) was given into the pericardial space for 30 min (LU group). Six dogs received ET-1 infusion without LU treatment (control group). Mean arterial blood pressure (MAP), cardiac output, electrocardiograph (ECG), right ventricular endocardial and epicardial (RVEND, RVEP), and left ventricular endocardial and epicardial (LVEND, LVEP) monophasic action potential durations (MAPDs) were recorded. No significant changes were observed in MAP and cardiac output. MAPD90s did not change significantly in the LU group (basic vs ET 20min: RVEP, 186 +/-7 vs 190 +/- 7; LVEP, 189 +/- 8 vs 201 +/- 11; RVEND, 191 +/- 10 vs 192 +/- 9; LVEND, 199 +/- 11 vs 203 +/- 11 ms), while significant MAPD90 prolongation was found in all investigated regions of the control group (ET start vs ET 20 min: LVEP, 174 +/- 3 vs 208 +/- 10*; RVEND, 206 +/- 9 vs 241 +/- 12* ms, *p < 0.05). No early after depolarization (EAD) was observed in the LU group, while EADs occurred in three controls. In the LU group, we have not found any significant arrhythmias except nonsustained ventricular tachycardias (nsVTs) in one animal. In the control group incessant nsVTs were observed in six, sustained VTs (sVTs) in four and ventricular fibrillation (VF) in two instances. Significant ST-elevation was observed in all animals in the LU and control groups (LU: 6.7 +/- 2.1 mV; control: 10.1 +/- 2.0 mV, p = NS). In conclusion, the arrhythmogenic action and the main electrophysiological effects of pericardial ET-1 infusion, MAPD prolongation and EAD formation, are inhibited by LU. However, LU could not prevent the ischemic changes resulting from ET-1 infusion.
No takes yet. Share an insight, caveat, or question.
Kiss et al. (2000) studied ET-1-induced ventricular arrhythmias (n=12). LU 135.252 vs. ET-1 infusion without LU treatment was evaluated on Ventricular arrhythmias and MAPD prolongation. LU 135.252 inhibited the arrhythmogenic action, MAPD prolongation, and early after depolarization formation caused by pericardial ET-1 infusion in dogs, but did not prevent ischemic changes.
Synapse has enriched 10 related papers. Consider them for comparative context: